APA

Paridaens R., Focan C., Michel J., Piccart M., Salamon E., Beauduin M., Closon M. T., Tueni E., Vindevoghel A. & Majois F. (19900711). Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. : Cancer chemotherapy and pharmacology.

Chicago

Paridaens R, Focan C, Michel J, Piccart M, Salamon E, Beauduin M, Closon M T, Tueni E, Vindevoghel A and Majois F. 19900711. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. : Cancer chemotherapy and pharmacology.

Harvard

Paridaens R., Focan C., Michel J., Piccart M., Salamon E., Beauduin M., Closon M. T., Tueni E., Vindevoghel A. and Majois F. (19900711). Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. : Cancer chemotherapy and pharmacology.

MLA

Paridaens R, Focan C, Michel J, Piccart M, Salamon E, Beauduin M, Closon M T, Tueni E, Vindevoghel A and Majois F. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. : Cancer chemotherapy and pharmacology. 19900711.